Sandoz and Henlius Turn Biosimilar Rights Into a Repeatable Launch Engine

Sandoz and Henlius are scaling biosimilar launches by splitting global rights from development and manufacturing, creating a repeatable model for patent-cliff growth.

Updated

What is this trend?

Sandoz and Henlius are turning biosimilar licensing into a repeatable launch model by separating global commercialization rights from development and manufacturing, speeding access to patent-cliff opportunities.

  • Expanded alliance now covers up to 10 mAb and ADC biosimilar assets
  • Sandoz gets ex-China commercialization rights; Henlius keeps development and manufacturing
  • Rights packages are becoming more valuable than one-off asset licenses
  • Patent cliffs are pushing demand for launch-ready biosimilar portfolios
  • CMC, regulatory execution, and market access are now core deal value drivers

What’s the latest?

Henlius and Sandoz expanded their biosimilars alliance to as many as 10 proposed monoclonal antibody and ADC assets, extending the April 2025 HLX13 deal into a repeatable portfolio model.

Biosimilar rights become launch engines, AI enters regulated trial operations, and margins come under pressure

How it developed

  1. IP Clarity, Mega-Rounds, and Approval-Contingent Capital Redefine Biotech Dealmaking
    • Asset Control and IP Clarity Are Replacing Platform-Led Growth

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Biotechnology

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.